David M Schuster

List of Publications by Year in Descending Order

149 papers	4,082 citations	34 h-index	60 g-index
160 ext. papers	4,816 ext. citations	3.8 avg, IF	5.4 L-index

#	Paper	IF	Citations
149	ACR Appropriateness Criteria Staging and Surveillance of Testicular Cancer: 2021 Update.. *Journal of the American College of Radiology*, **2022**, 19, S194-S207	3.5	0
148	Predictors and Real-World Use of Prostate-Specific Radioligand Therapy: PSMA and Beyond. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2022**, 1-17	7.1	0
147	Prostate Cancer Liver Metastases Presenting as Relatively Photopenic Lesions on 18F-Fluciclovine PET/CT. *Clinical Nuclear Medicine*, **2021**, 46, e240-e241	1.7	1
146	Exploratory study of F-fluciclovine pet/ct for response assessment to docetaxel in patients with metastatic castration-resistant prostate cancer. *American Journal of Nuclear Medicine and Molecular Imaging*, **2021**, 11, 218-229	2.2	0
145	Ring Sclerosis in Prostate Cancer: Circle of Malignancy or Benignity?. *Clinical Nuclear Medicine*, **2021**, 46, e286-e289	1.7	
144	Yttrium-90 dosimetry and implications on tumour response and survival after radioembolisation of chemo-refractory hepatic metastases from breast cancer. *Nuclear Medicine Communications*, **2021**, 42, 402-409	1.6	3
143	Determination of tumour dose response threshold and implication on survival in patients with HCC treated with Y90 radiation segmentectomy: a simple semi-quantitative analysis. *Nuclear Medicine Communications*, **2021**, 42, 892-898	1.6	0
142	Determination of Tumor Dose Response Thresholds in Patients with Chemorefractory Intrahepatic Cholangiocarcinoma Treated with Resin and Glass-based Y90 Radioembolization. *CardioVascular and Interventional Radiology*, **2021**, 44, 1194-1203	2.7	3
141	Same day yttrium-90 radioembolization with single photon emission computed tomography/computed tomography: An opportunity to improve care during the COVID-19 pandemic and beyond. *World Journal of Gastrointestinal Oncology*, **2021**, 13, 440-452	3.4	0
140	F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2/3 randomised controlled trial. *Lancet, The*, **2021**, 397, 1895-1904	40	29
139	F-Fluciclovine PET/CT performance in biochemical recurrence of prostate cancer: a systematic review. *Prostate Cancer and Prostatic Diseases*, **2021**, 24, 997-1006	6.2	5
138	Tumor-to-Normal Ratio Relationship between Planning Technetium-99 Macroaggregated Albumin and Posttherapy Yttrium-90 Bremsstrahlung SPECT/CT. *Journal of Vascular and Interventional Radiology*, **2021**, 32, 752-760	2.4	3
137	Comparison of Tc-99m MAA Planar Versus SPECT/CT Imaging for Lung Shunt Fraction Evaluation Prior to Y-90 Radioembolization: Are We Overestimating Lung Shunt Fraction?. *CardioVascular and Interventional Radiology*, **2021**, 44, 254-260	2.7	3
136	Role of F-Fluciclovine and Prostate-Specific Membrane Antigen PET/CT in Guiding Management of Oligometastatic Prostate Cancer: Expert Panel Narrative Review. *American Journal of Roentgenology*, **2021**, 216, 851-859	5.4	3
135	Salvage Radiotherapy Management Decisions in Postprostatectomy Patients with Recurrent Prostate Cancer Based on F-Fluciclovine PET/CT Guidance. *Journal of Nuclear Medicine*, **2021**, 62, 1089-1096	8.9	1
134	Improved Tumor Response in Patients on Metformin Undergoing Yttrium-90 Radioembolization Segmentectomy for Hepatocellular Carcinoma. *CardioVascular and Interventional Radiology*, **2021**, 44, 1937-1944	2.7	1
133	PET Imaging for Prostate Cancer. *Radiologic Clinics of North America*, **2021**, 59, 801-811	2.3	6

132	Clinical utility of F-Fluciclovine PET/CT in recurrent prostate cancer with very low (≤0.3 ng/mL) prostate-specific antigen levels. *American Journal of Nuclear Medicine and Molecular Imaging*, **2021**, 11, 406-414	2.2	1
131	[F]-Fluciclovine PET discrimination of recurrent intracranial metastatic disease from radiation necrosis. *EJNMMI Research*, **2020**, 10, 148	3.6	4
130	Incidental Detection of Lung Adenocarcinoma Presenting as an Anterior Mediastinal Mass on 18F-Fluciclovine PET/CT in a Patient With Primary Prostate Cancer. *Clinical Nuclear Medicine*, **2020**, 45, e525-e527	1.7	0
129	ACR Appropriateness Criteria® Recurrent Lower Urinary Tract Infections in Females. *Journal of the American College of Radiology*, **2020**, 17, S487-S496	3.5	1
128	Radiologic Assessment of Esophageal Cancer **2020**, 139-157		
127	F-Fluciclovine Positron Emission Tomography in Men With Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy and Planning to Undergo Salvage Radiation Therapy: Results from LOCATE. *Practical Radiation Oncology*, **2020**, 10, 354-362	2.8	5
126	Yttrium-90 Radioembolization Dosimetry: What Trainees Need to Know. *Seminars in Interventional Radiology*, **2020**, 37, 543-554	1.6	3
125	[F]Fluciclovine Positron Emission Tomography/Computerized Tomography for Preoperative Staging in Patients with Intermediate to High Risk Primary Prostate Cancer. *Journal of Urology*, **2020**, 204, 734-740	2.5	11
124	Incidence of Radioembolization-Induced Liver Disease and Liver Toxicity Following Repeat 90Y-Radioembolization: Outcomes at a Large Tertiary Care Center. *Clinical Nuclear Medicine*, **2020**, 45, 100-104	1.7	8
123	[F]Fluciclovine PET/CT: joint EANM and SNMMI procedure guideline for prostate cancer imaging-version 1.0. *European Journal of Nuclear Medicine and Molecular Imaging*, **2020**, 47, 579-591	8.8	25
122	Characterizing and Mitigating Bladder Radioactivity on F-Fluciclovine PET/CT. *Journal of Nuclear Medicine Technology*, **2020**, 48, 24-29	1.1	1
121	Role of novel imaging in the management of prostate cancer. *Urologic Oncology: Seminars and Original Investigations*, **2019**, 37, 611-618	2.8	10
120	F-Fluciclovine Parameters on Targeted Prostate Biopsy Associated with True Positivity in Recurrent Prostate Cancer. *Journal of Nuclear Medicine*, **2019**, 60, 1531-1536	8.9	8
119	Fluorine-18-Labeled Fluciclovine PET/CT in Clinical Practice: Factors Affecting the Rate of Detection of Recurrent Prostate Cancer. *American Journal of Roentgenology*, **2019**, 213, 851-858	5.4	18
118	ACR Appropriateness Criteria® Lower Urinary Tract Symptoms-Suspicion of Benign Prostatic Hyperplasia. *Journal of the American College of Radiology*, **2019**, 16, S378-S383	3.5	3
117	Deep learning-based three-dimensional segmentation of the prostate on computed tomography images. *Journal of Medical Imaging*, **2019**, 6, 025003	2.6	2
116	A semiautomatic approach for prostate segmentation in MR images using local texture classification and statistical shape modeling. *Proceedings of SPIE*, **2019**, 10951,	1.7	1
115	The Impact of Positron Emission Tomography with 18F-Fluciclovine on the Treatment of Biochemical Recurrence of Prostate Cancer: Results from the LOCATE Trial. *Journal of Urology*, **2019**, 201, 322-331	2.5	81

114	Feasibility and Initial Results: Fluciclovine Positron Emission Tomography/Ultrasound Fusion Targeted Biopsy of Recurrent Prostate Cancer. *Journal of Urology*, **2019**, 202, 413-421	2.5	6
113	Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [F]FDG: version 1.0. *European Journal of Nuclear Medicine and Molecular Imaging*, **2019**, 46, 540-557	8.8	198
112	Update on F-Fluciclovine PET for Prostate Cancer Imaging. *Journal of Nuclear Medicine*, **2018**, 59, 733-738	8.9	78
111	A semiautomatic segmentation method for prostate in CT images using local texture classification and statistical shape modeling. *Medical Physics*, **2018**, 45, 2527-2541	4.4	9
110	Y radioembolization dosimetry using a simple semi-quantitative method in intrahepatic cholangiocarcinoma: Glass versus resin microspheres. *Nuclear Medicine and Biology*, **2018**, 59, 22-28	2.1	10
109	Bayesian penalised likelihood reconstruction (Q.Clear) of F-fluciclovine PET for imaging of recurrent prostate cancer: semi-quantitative and clinical evaluation. *British Journal of Radiology*, **2018**, 91, 20170727	3.4	20
108	Prospective evaluation of fluciclovine (F) PET-CT and MRI in detection of recurrent prostate cancer in non-prostatectomy patients. *European Journal of Radiology*, **2018**, 102, 1-8	4.7	28
107	Current Clinical Practice Patterns of Self-Identified Nuclear Medicine Specialists. *American Journal of Roentgenology*, **2018**, 211, 978-985	5.4	3
106	A semiautomatic algorithm for three-dimensional segmentation of the prostate on CT images using shape and local texture characteristics. *Proceedings of SPIE*, **2018**, 10576,	1.7	3
105	[F]Fluciclovine PET discrimination between high- and low-grade gliomas. *EJNMMI Research*, **2018**, 8, 67	3.6	26
104	ACR Appropriateness Criteria Post-treatment Follow-up Prostate Cancer. *Journal of the American College of Radiology*, **2018**, 15, S132-S149	3.5	19
103	ACR Appropriateness Criteria Pretreatment Staging of Muscle-Invasive Bladder Cancer. *Journal of the American College of Radiology*, **2018**, 15, S150-S159	3.5	28
102	Amino Acid Metabolism as a Target for Breast Cancer Imaging. *PET Clinics*, **2018**, 13, 437-444	2.2	10
101	Imaging of Prostate Cancer Using Fluciclovine. *Urologic Clinics of North America*, **2018**, 45, 489-502	2.9	25
100	Imaging of Prostate Cancer Using Fluciclovine. *PET Clinics*, **2017**, 12, 145-157	2.2	33
99	Automatic segmentation of the prostate on CT images using deep learning and multi-atlas fusion. *Proceedings of SPIE*, **2017**, 10133,	1.7	18
98	Molecular imaging and fusion targeted biopsy of the prostate. *Clinical and Translational Imaging*, **2017**, 5, 29-43	2	8
97	Re: "Cost-Savings Analysis of Renal Scintigraphy, Stratified by Renal Function Thresholds: Mercaptoacetyltriglycine Versus Diethylene Triamine Penta-Acetic Acid". *Journal of the American College of Radiology*, **2017**, 14, 146	3.5	1

96	ACR Appropriateness Criteria Prostate Cancer-Pretreatment Detection, Surveillance, and Staging. *Journal of the American College of Radiology*, **2017**, 14, S245-S257	3.5	30
95	PET Molecular Imaging-Directed Biopsy: A Review. *American Journal of Roentgenology*, **2017**, 209, 255-269	3.4	25
94	Change in Salvage Radiotherapy Management Based on Guidance With FACBC (Fluciclovine) PET/CT in Postprostatectomy Recurrent Prostate Cancer. *Clinical Nuclear Medicine*, **2017**, 42, e22-e28	1.7	72
93	PET Tracer F-Fluciclovine Can Detect Histologically Proven Bone Metastatic Lesions: A Preclinical Study in Rat Osteolytic and Osteoblastic Bone Metastasis Models. *Theranostics*, **2017**, 7, 2048-2064	12.1	14
92	A combined learning algorithm for prostate segmentation on 3D CT images. *Medical Physics*, **2017**, 44, 5768-5781	4.4	14
91	Multisite Experience of the Safety, Detection Rate and Diagnostic Performance of Fluciclovine (F) Positron Emission Tomography/Computerized Tomography Imaging in the Staging of Biochemically Recurrent Prostate Cancer. *Journal of Urology*, **2017**, 197, 676-683	2.5	130
90	Impact of F-Fluciclovine PET on Target Volume Definition for Postprostatectomy Salvage Radiotherapy: Initial Findings from a Randomized Trial. *Journal of Nuclear Medicine*, **2017**, 58, 412-418	8.9	30
89	Radionuclide Therapies in Molecular Imaging and Precision Medicine. *PET Clinics*, **2017**, 12, 93-103	2.2	3
88	Fasting Enhances the Contrast of Bone Metastatic Lesions in F-Fluciclovine-PET: Preclinical Study Using a Rat Model of Mixed Osteolytic/Osteoblastic Bone Metastases. *International Journal of Molecular Sciences*, **2017**, 18,	6.3	9
87	Multisite experience of fluciclovine (18F) PET/CT imaging in biochemically recurrent prostate cancer: Impact of clinical factors and intersite variation.. *Journal of Clinical Oncology*, **2017**, 35, 163-163	2.2	1
86	PET Tracers Beyond FDG in Prostate Cancer. *Seminars in Nuclear Medicine*, **2016**, 46, 507-521	5.4	48
85	Is There a Role for PET/CT Parameters to Characterize Benign, Malignant, and Metastatic Parotid Tumors?. *American Journal of Roentgenology*, **2016**, 207, 635-40	5.4	12
84	Combining Population and Patient-Specific Characteristics for Prostate Segmentation on 3D CT Images. *Proceedings of SPIE*, **2016**, 9784,	1.7	7
83	Image Guided Planning for Prostate Carcinomas With Incorporation of Anti-3-[18F]FACBC (Fluciclovine) Positron Emission Tomography: Workflow and Initial Findings From a Randomized Trial. *International Journal of Radiation Oncology Biology Physics*, **2016**, 96, 206-13	4	22
82	Random Walk Based Segmentation for the Prostate on 3D Transrectal Ultrasound Images. *Proceedings of SPIE*, **2016**, 9786,	1.7	1
81	Is there a role for PET/CT parameters to differentiate thyroid cartilage invasion from penetration?. *European Journal of Radiology*, **2016**, 85, 319-23	4.7	3
80	Focal Hepatic Hot Spot From Superior Vena Cava Occlusion Visualized on Ventilation/Perfusion Scintigraphy With Contrast-Enhanced CT Correlate. *Clinical Nuclear Medicine*, **2016**, 41, 401-2	1.7	2
79	90Y Radioembolization Lung Shunt Fraction in Primary and Metastatic Liver Cancer as a Biomarker for Survival. *Clinical Nuclear Medicine*, **2016**, 41, 21-7	1.7	22

78	Anti-3-18F-FACBC (18F-Fluciclovine) PET/CT of Breast Cancer: An Exploratory Study. *Journal of Nuclear Medicine*, **2016**, 57, 1357-63	8.9	39
77	Recurrent prostate cancer detection with anti-3-[(18)F]FACBC PET/CT: comparison with CT. *European Journal of Nuclear Medicine and Molecular Imaging*, **2016**, 43, 1773-83	8.8	115
76	Evaluation of Prostate Cancer with Radiolabeled Amino Acid Analogs. *Journal of Nuclear Medicine*, **2016**, 57, 61S-66S	8.9	29
75	Reproducibility and reliability of anti-3-[□□]FACBC uptake measurements in background structures and malignant lesions on follow-up PET-CT in prostate carcinoma: an exploratory analysis. *Molecular Imaging and Biology*, **2015**, 17, 277-83	3.8	10
74	The nuclear medicine therapy care coordination service: a model for radiologist-driven patient-centered care. *Academic Radiology*, **2015**, 22, 771-8	4.3	4
73	Octreoscan Versus FDG-PET for Neuroendocrine Tumor Staging: A Biological Approach. *Annals of Surgical Oncology*, **2015**, 22, 2295-301	3.1	61
72	Do 18F-FDG PET/CT parameters in oropharyngeal and oral cavity squamous cell carcinomas indicate HPV status?. *Clinical Nuclear Medicine*, **2015**, 40, e196-200	1.7	22
71	Whole-body immunoPET reveals active SIV dynamics in viremic and antiretroviral therapy-treated macaques. *Nature Methods*, **2015**, 12, 427-32	21.6	113
70	[(14)C]Fluciclovine (alias anti-[(14)C]FACBC) uptake and ASCT2 expression in castration-resistant prostate cancer cells. *Nuclear Medicine and Biology*, **2015**, 42, 887-92	2.1	34
69	(90)Y Radioembolization: Multimodality Imaging Pattern Approach with Angiographic Correlation for Optimized Target Therapy Delivery. *Radiographics*, **2015**, 35, 1602-18	5.4	20
68	18F-FDG-PET/CT parameters as imaging biomarkers in oral cavity squamous cell carcinoma, is visual analysis of PET and contrast enhanced CT better than the numbers?. *European Journal of Radiology*, **2015**, 84, 1171-6	4.7	10
67	Molecular imaging of advanced prostate cancer. *Current Problems in Cancer*, **2015**, 39, 29-32	2.3	2
66	Radiologic Assessment of Esophageal Cancer **2015**, 105-121		
65	Differences in transport mechanisms of trans-1-amino-3-[18F]fluorocyclobutanecarboxylic acid in inflammation, prostate cancer, and glioma cells: comparison with L-[methyl-11C]methionine and 2-deoxy-2-[18F]fluoro-D-glucose. *Molecular Imaging and Biology*, **2014**, 16, 322-9	3.8	59
64	Accumulation of trans-1-amino-3-[(18)F]fluorocyclobutanecarboxylic acid in prostate cancer due to androgen-induced expression of amino acid transporters. *Molecular Imaging and Biology*, **2014**, 16, 756-64	3.8	28
63	A simple method for estimating dose delivered to hepatocellular carcinoma after yttrium-90 glass-based radioembolization therapy: preliminary results of a proof of concept study. *Journal of Vascular and Interventional Radiology*, **2014**, 25, 277-87	2.4	36
62	Anti-3-[(18)F]FACBC positron emission tomography-computerized tomography and (111)In-capromab pendetide single photon emission computerized tomography-computerized tomography for recurrent prostate carcinoma: results of a prospective clinical trial. *Journal of Urology*, **2014**, 191, 1446-53	2.5	141
61	Anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid: physiologic uptake patterns, incidental findings, and variants that may simulate disease. *Journal of Nuclear Medicine*, **2014**, 55, 1986-92	8.9	112

60	A rare presentation of myocardial plasmacytoma assessed by FDG PET/CT. *Clinical Nuclear Medicine*, **2014**, 39, 643-5	1.7	6
59	Quantitative dosimetry for yttrium-90 radionuclide therapy: tumor dose predicts fluorodeoxyglucose positron emission tomography response in hepatic metastatic melanoma. *Journal of Vascular and Interventional Radiology*, **2014**, 25, 288-95	2.4	25
58	Local recurrence patterns in breast cancer patients treated with oncoplastic reduction mammaplasty and radiotherapy. *Annals of Surgical Oncology*, **2014**, 21, 93-9	3.1	46
57	Four-dimensional (4D) motion detection to correct respiratory effects in treatment response assessment using molecular imaging biomarkers. *TCRT Express*, **2014**, 13, 571-82		
56	Imaging quality of F-18-FDG PET/CT in the inpatient versus outpatient setting. *Annals of Nuclear Medicine*, **2013**, 27, 508-14	2.5	1
55	Pilot study of the utility of the synthetic PET amino-acid radiotracer anti-1-amino-3-[(18)F]fluorocyclobutane-1-carboxylic acid for the noninvasive imaging of pulmonary lesions. *Molecular Imaging and Biology*, **2013**, 15, 633-43	3.8	24
54	Differences in neural activation for object-directed grasping in chimpanzees and humans. *Journal of Neuroscience*, **2013**, 33, 14117-34	6.6	64
53	Radiation field design and patterns of locoregional recurrence following definitive radiotherapy for breast cancer. *International Journal of Radiation Oncology Biology Physics*, **2013**, 85, 309-14	4	7
52	Comparative evaluation of transport mechanisms of trans-1-amino-3-[□F]fluorocyclobutanecarboxylic acid and L-[methyl-□□C]methionine in human glioma cell lines. *Brain Research*, **2013**, 1535, 24-37	3.7	35
51	Kinetic analyses of trans-1-amino-3-[18F]fluorocyclobutanecarboxylic acid transport in Xenopus laevis oocytes expressing human ASCT2 and SNAT2. *Nuclear Medicine and Biology*, **2013**, 40, 670-5	2.1	45
50	Accuracy Evaluation of a 3D Ultrasound-guided Biopsy System. *Proceedings of SPIE*, **2013**, 8671,	1.7	3
49	Characterization of primary prostate carcinoma by anti-1-amino-2-[(18)F] -fluorocyclobutane-1-carboxylic acid (anti-3-[(18)F] FACBC) uptake. *American Journal of Nuclear Medicine and Molecular Imaging*, **2013**, 3, 85-96	2.2	60
48	PET-directed, 3D Ultrasound-guided prostate biopsy **2013**, 29, 12-15		12
47	PERCIST criteria to predict survival at 3 months following intra-arterial resin-based yttrium-90 (Y-90) radioembolization therapy of unresectable intrahepatic cholangiocarcinoma refractory to standard chemotherapy: A proof of concept study.. *Journal of Clinical Oncology*, **2013**, 31, e15141-e15141	2.2	
46	Radiohalogenated nonnatural amino acids as PET and SPECT tumor imaging agents. *Medicinal Research Reviews*, **2012**, 32, 868-905	14.4	74
45	Prognostic value of 18f-fluorodeoxyglucose positron emission tomography-computed tomography in predicting survival in patients with unresectable metastatic melanoma to the liver undergoing yttrium-90 radioembolization. *Journal of Vascular and Interventional Radiology*, **2012**, 23, 943-8	2.4	20
44	Transport mechanisms of trans-1-amino-3-fluoro[1-(14)C]cyclobutanecarboxylic acid in prostate cancer cells. *Nuclear Medicine and Biology*, **2012**, 39, 109-19	2.1	94
43	Metastatic Breast Lesion to the Falx Detected with PET-CT. *Nuclear Medicine and Molecular Imaging*, **2012**, 46, 147-9	1.9	

42	Heme products post-radiofrequency ablation obscure tumor recurrence on MR but not on PET-CT. *Nuclear Medicine and Molecular Imaging*, **2012**, 46, 152-4	1.9	
41	Hyperspectral imaging and quantitative analysis for prostate cancer detection. *Journal of Biomedical Optics*, **2012**, 17, 076005	3.5	149
40	A Molecular Image-directed, 3D Ultrasound-guided Biopsy System for the Prostate. *Proceedings of SPIE*, **2012**, 2012,	1.7	18
39	□□In OctreoScan SPECT-MRI fusion for the detection of a pancreatic insulinoma. *Clinical Nuclear Medicine*, **2012**, 37, e53-6	1.7	2
38	Absent coronary artery calcium excludes inducible myocardial ischemia on computed tomography/positron emission tomography. *International Journal of Cardiology*, **2011**, 147, 424-7	3.2	27
37	Biodistribution and human dosimetry of enantiomer-1 of the synthetic leucine analog anti-1-amino-2-fluorocyclopentyl-1-carboxylic acid. *Nuclear Medicine and Biology*, **2011**, 38, 1035-41	2.1	2
36	Unusual presentations of metastatic prostate carcinoma as detected by anti-3 F-18 FACBC PET/CT. *Clinical Nuclear Medicine*, **2011**, 36, 800-2	1.7	9
35	Pilot evaluation of anti-1-amino-2-[18F] fluorocyclopentane-1-carboxylic acid (anti-2-[18F] FACPC) PET-CT in recurrent prostate carcinoma. *Molecular Imaging and Biology*, **2011**, 13, 1272-7	3.8	13
34	Automatic 3D Segmentation of Ultrasound Images Using Atlas Registration and Statistical Texture Prior. *Proceedings of SPIE*, **2011**, 7964,	1.7	22
33	Detection of recurrent prostate carcinoma with anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid PET/CT and 111In-capromab pendetide SPECT/CT. *Radiology*, **2011**, 259, 852-61	20.5	128
32	A PET/CT Directed, 3D Ultrasound-Guided Biopsy System for Prostate Cancer. *Lecture Notes in Computer Science*, **2011**, 6363, 100-108	0.9	9
31	MR-based attenuation correction for hybrid PET-MR brain imaging systems using deformable image registration. *Medical Physics*, **2010**, 37, 2101-9	4.4	94
30	Posterior bladder layering of excreted 18F-FDG on PET/CT. *Nuclear Medicine Communications*, **2010**, 31, 859-63	1.6	3
29	Prompt-gamma compensation in Rb-82 myocardial perfusion 3D PET/CT. *Journal of Nuclear Cardiology*, **2010**, 17, 247-53	2.1	44
28	Initial experience with the radiotracer anti-1-amino-3-[18F]Fluorocyclobutane-1-carboxylic acid (anti-[18F]FACBC) with PET in renal carcinoma. *Molecular Imaging and Biology*, **2009**, 11, 434-8	3.8	50
27	Case study of anti-1-amino-3-F-18 fluorocyclobutane-1-carboxylic acid (anti-[F-18] FACBC) to guide prostate cancer radiotherapy target design. *Clinical Nuclear Medicine*, **2009**, 34, 279-84	1.7	14
26	Breast angiosarcoma: FDG PET findings. *Clinical Nuclear Medicine*, **2009**, 34, 443-5	1.7	15
25	Investigation of emission-transmission misalignment artifacts on rubidium-82 cardiac PET with adenosine pharmacologic stress. *Molecular Imaging and Biology*, **2008**, 10, 201-8	3.8	8

24	Biodistribution and radiation dosimetry of the synthetic nonmetabolized amino acid analogue anti-18F-FACBC in humans. *Journal of Nuclear Medicine*, **2007**, 48, 1017-20	8.9	79
23	Sarcoid-like reaction in the spleen following chemotherapy for non-Hodgkin's lymphoma. *Clinical Nuclear Medicine*, **2007**, 32, 569-71	1.7	10
22	Initial experience with the radiotracer anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma. *Journal of Nuclear Medicine*, **2007**, 48, 56-63	8.9	189
21	Radionuclide imaging for hyperparathyroidism (HPT): which is the best technetium-99m sestamibi modality?. *Surgery*, **2006**, 140, 856-63; discussion 863-5	3.6	62
20	PET-CT vs contrast-enhanced CT: what is the role for each after chemoradiation for advanced oropharyngeal cancer?. *Head and Neck*, **2006**, 28, 487-95	4.2	34
19	Gastrointestinal tract malignancies and positron emission tomography: an overview. *Seminars in Nuclear Medicine*, **2006**, 36, 169-81	5.4	60
18	Choroidal melanoma with hematogenous spread to the liver: F-18 FDG PET/CT findings. *Clinical Nuclear Medicine*, **2006**, 31, 347-8	1.7	2
17	Xanthogranulomatous pyelonephritis characterized on PET/CT. *Clinical Nuclear Medicine*, **2005**, 30, 728-9	1.7	14
16	Comparison of CT- and FDG-PET-defined gross tumor volume in intensity-modulated radiotherapy for head-and-neck cancer. *International Journal of Radiation Oncology Biology Physics*, **2005**, 61, 1385-92	4	213
15	F-18 FDG PET-CT fusion in radiotherapy treatment planning for head and neck cancer. *Head and Neck*, **2005**, 27, 494-502	4.2	103
14	CT with histopathologic correlation of FDG uptake in a patient with pulmonary granuloma and pleural plaque caused by remote talc pleurodesis. *American Journal of Roentgenology*, **2004**, 182, 92-4	5.4	13
13	Molecular imaging in breast cancer. *Radiologic Clinics of North America*, **2004**, 42, 885-908, vi-vii	2.3	8
12	Central line injection artifact simulating paratracheal adenopathy on FDG PET imaging. *Clinical Nuclear Medicine*, **2004**, 29, 735-7	1.7	5
11	Involving users in the implementation of an imaging order entry system. *Journal of the American Medical Informatics Association: JAMIA*, **2003**, 10, 315-21	8.6	17
10	Gallium and other agents in diseases of the lung. *Seminars in Nuclear Medicine*, **2002**, 32, 193-211	5.4	38
9	Jejunal diverticular hemorrhage localized by red blood cell scintigraphy. *Clinical Nuclear Medicine*, **2001**, 26, 936-7	1.7	5
8	Malignant supraclavicular lymph node visualization during Tc-99m HDP bone imaging. *Clinical Nuclear Medicine*, **2000**, 25, 376-7	1.7	0
7	One possible future. *Journal of Alternative and Complementary Medicine*, **1998**, 4, 255-6	2.4	

6	The use of the diagnostic radionuclide ascites scan to facilitate treatment decisions for hepatic hydrothorax. *Clinical Nuclear Medicine*, **1998**, 23, 16-8	1.7	19
5	Esophageal scarring causing false-positive uptake on I-131 whole-body imaging. *Clinical Nuclear Medicine*, **1998**, 23, 334	1.7	14
4	Artifactual perfusion defect from a hypertrophic first costosternal articulation. *Clinical Nuclear Medicine*, **1997**, 22, 642	1.7	
3	The malady of incomplete, inadequate, and inaccurate radiology requisition histories: a computerized treatment. *American Journal of Roentgenology*, **1996**, 167, 855-9	5.4	16
2	The integrative hospital explored via acupuncture. *Journal of Alternative and Complementary Medicine*, **1996**, 2, 503-14	2.4	2
1	Magnetic resonance cholangiography. *Abdominal Imaging*, **1995**, 20, 353-6		11